Clinical Significance of p53 and p16ink4a Status in a Contemporary North American Penile Carcinoma Cohort

Show simple item record

dc.contributor.author Zargar Shoshtari, Kamran en
dc.contributor.author Spiess, PE en
dc.contributor.author Berglund, AE en
dc.contributor.author Sharma, P en
dc.contributor.author Powsang, JM en
dc.contributor.author Giuliano, A en
dc.contributor.author Magliocco, AM en
dc.contributor.author Dhillon, J en
dc.date.accessioned 2016-10-17T03:18:37Z en
dc.date.issued 2016-08 en
dc.identifier.citation Clinical Genitourinary Cancer, 2016, 14(4), pp. 346-351 en
dc.identifier.issn 1558-7673 en
dc.identifier.uri http://hdl.handle.net/2292/30763 en
dc.description.abstract Background: Because of the low incidence of penile carcinoma (PC), the value of p16ink4a, p53, and human papilloma virus (HPV) infection status in clinical practice remains unclear. Herein, we report our experience with potential clinical utility of these markers in men with PC treated at our institution. Patients and Methods: Tissue microarrays of 57 cases of invasive penile squamous cell carcinomas were immunohistochemically stained for p16 and p53. HPV in situ hybridization (ISH) for high-risk subtypes was also performed. Association between marker status, nodal disease, overall (OS) and cancer-specific survival (CSS) were assessed. Results: p16 and HPV ISH were positive in 23 (40%) and 24 (42%) of the cohort, respectively. The proportion of warty, basaloid, or mixed warty basaloid tumor subtypes were significantly greater in the p16-positive patients (48% vs. 3%; P < .01). p53 expression was negative in 31 (54%) cases. Only in p16-negative patients, positive p53 status was associated with pN+ disease (odds ratio, 4.4 [95% confidence interval (CI), 1.04-18.6]). In Kaplan–Meier analysis, the unadjusted estimated OS was insignificantly longer in p16-positive patients (median OS, 75 vs. 27 months; P = .27) and median CSS was not reached (P = .16). In a multivariable Cox proportional hazard model, when controlling for pathological nodal status and adjuvant chemotherapy, p16 status was a significant predictor for improved CSS (hazard ratio, 0.36 [95% CI, 0.13-0.99]). The worst CSS was seen in pN+ patients with double negative p16 and p53 expression (8 vs. 34 months; P = .01). Conclusion: In this current cohort, p53 and p16 status showed clinical utility in predicting nodal disease as well as survival. en
dc.description.uri http://www.journals.elsevier.com/clinical-genitourinary-cancer/ en
dc.publisher Elsevier en
dc.relation.ispartofseries Clinical Genitourinary Cancer en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/1558-7673/ en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.title Clinical Significance of p53 and p16ink4a Status in a Contemporary North American Penile Carcinoma Cohort en
dc.type Journal Article en
dc.identifier.doi 10.1016/j.clgc.2015.12.019 en
pubs.issue 4 en
pubs.begin-page 346 en
pubs.volume 14 en
dc.rights.holder Copyright: Elsevier en
dc.identifier.pmid 26794389 en
pubs.author-url http://www.clinical-genitourinary-cancer.com/article/S1558-7673(15)00349-3/fulltext en
pubs.end-page 351 en
pubs.publication-status Published en
dc.rights.accessrights http://purl.org/eprint/accessRights/RestrictedAccess en
pubs.subtype Article en
pubs.elements-id 540647 en
pubs.org-id Medical and Health Sciences en
pubs.org-id School of Medicine en
pubs.org-id Surgery Department en
dc.identifier.eissn 1938-0682 en
pubs.record-created-at-source-date 2016-10-17 en
pubs.dimensions-id 26794389 en


Files in this item

Find Full text

This item appears in the following Collection(s)

Show simple item record

Share

Search ResearchSpace


Browse

Statistics